Large Review Study Says Avastin Offers Only Modest Benefits for Metastatic Breast Cancer
Avastin (chemical name: bevacizumab) is a targeted therapy that was approved in 2008 by the U.S. Food and Drug Administration (FDA) to be used in combination with Taxol (chemical name: paclitaxel) to treat metastatic, HER2-negative breast cancer that hadn’t yet been treated with chemotherapy. On Nov. 18, 2011, the FDA announced it had removed the […]
read more